Type 2 diabetes: Devices and technology

Use of intermittently scanned continuous glucose monitoring is associated with an increased likelihood for treatment intensification in people with type 2 diabetes, a study shows.

A short period of intermittently scanned continuous glucose monitoring prior to a first endocrinologist consultation can improve glycemic outcomes for people with type 2 diabetes, report the SPOT FIRST study researchers.

Fully subsidizing continuous glucose monitors could overcome disparities in their use by people with diabetes, suggests research conducted in adults enrolled in a US Medicaid program.

Brief, repeated use of real-time continuous glucose monitoring may help to improve glycemic control in people with type 2 diabetes who would otherwise need to escalate to insulin, suggests a small randomized trial.

Skin reactions to glucose monitors and insulin pumps occur in more than a quarter of users but only occasionally result in device discontinuation, research shows.

People taking basal insulin to treat type 2 diabetes experience a significant reduction in the risk for acute complications, which is sustained for at least 2 years after initiating use of the Freestyle Libre, say French researchers.

A fully closed-loop insulin delivery system markedly increases time in range for people with insulin-treated type 2 diabetes, shows a small randomized crossover trial.

A randomized trial shows that comprehensive care resulting in improved glycemic control among people with persistently poorly controlled type 2 diabetes can be delivered via telehealth.

An observational study suggests that initiating flash glucose monitoring might lead to a reduction in symptoms of depression in people with insulin-treated diabetes.

An artificial intelligence platform known as Whole Body Twin could be one answer to reversing type 2 diabetes, research suggests.

Early findings from the Hypo-METRICS trial indicate that people with diabetes are unaware on most of the occasions that their blood glucose dips into the hypoglycemic range.

The publication of two SURPASS-3 substudies in The Lancet Diabetes & Endocrinology reveals significant benefits of tirzepatide on liver and abdominal fat in people with type 2 diabetes, as well as on time in target glucose range.

The Dexcom G7 continuous glucose monitor is accurate and well tolerated for up to 10.5 days when worn on the arm or abdomen, a study of adults with diabetes suggests.

Structured monitoring of blood glucose improves its control regardless of the device used, although continuous glucose monitoring is better than self-monitored blood glucose for reducing hypoglycemia, shows a randomized trial.

Discontinuing continuous glucose monitoring leads to the loss of approximately half of the additional time in glycemic range accrued during its use among people with type 2 diabetes, MOBILE study data show.

Findings from an exploratory randomized crossover trial suggest that closed-loop insulin delivery leads to better glycemic control than standard insulin treatment in people with type 2 diabetes and end-stage renal disease requiring maintenance dialysis in the outpatient setting.

Gaining greater control of blood glucose and hypoglycemia awareness is associated with a reduction in diabetes distress among people who start using the FreeStyle Libre, researchers report.

Completing a brief, adaptive questionnaire prior to each consultation with healthcare providers can focus discussions toward the immediate priorities and concerns of people with diabetes, shows a feasibility study.

The results of two studies published in JAMA indicate that real-time continuous glucose monitoring benefits people with type 1 or type 2 diabetes on a range of insulin regimens and from a wide variety of backgrounds.

Analysis of older participants in the BRIGHT trial suggests that this subgroup may do slightly better with insulin glargine-300 than with degludec.